New AIDS Drug Clears
Fewer restrictions on use
TUESDAY, Oct. 21, 2003 (HealthDayNews) -- The U.S. Food and Drug Administration has approved the new GlaxoSmithKline anti-AIDS drug Lexiva (fosamprenavir calcium), among a class of drugs known as protease inhibitors.
The drug offers more flexible dosing than similar medicines, the company says. There are no food and water restrictions, and the two-pill dose can be taken once or twice daily with or without other drugs, versus as many as eight times daily with other anti-AIDS medicines.
The drug, formerly known as 908, was co-developed by Vertex Pharmaceuticals, a Boston-based biotech firm. The medication's safety and effectiveness was demonstrated in clinical trials involving more than 1,200 people, Glaxo says.